公开(公告)号：US07199244B2

公开(公告)日：2007-04-03

申请号：US10823372

申请日：2004-04-12

Applicant: Robert D. Groneberg ,  James Zhan ,  Benny C. Askew, Jr. ,  Derin C. D'Amico ,  Nianhe Han ,  Christopher H. Fotsch ,  Qingyian Liu ,  Babak Riahi ,  Jiawang Zhu ,  Kevin Yang ,  Jian Jeffrey Chen ,  Rana Nomak

Inventor： Robert D. Groneberg ,  James Zhan ,  Benny C. Askew, Jr. ,  Derin C. D'Amico ,  Nianhe Han ,  Christopher H. Fotsch ,  Qingyian Liu ,  Babak Riahi ,  Jiawang Zhu ,  Kevin Yang ,  Jian Jeffrey Chen ,  Rana Nomak

IPC: C07D211/08 ,  C07D405/00

CPC classification number: C07D207/48 ,  C07D211/96 ,  C07D215/58 ,  C07D217/22 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract translation: 所选化合物对于治疗疼痛和疾病如炎症介导的疾病是有效的。 本发明包括新的化合物，类似物，前药和其药学上可接受的衍生物，用于预防和治疗疾病和其它疾病或涉及疼痛，炎症等的病症的药物组合物和方法。 本发明还涉及制备这些化合物的方法以及在这些方法中有用的中间体。

公开(公告)号：US07144988B2

公开(公告)日：2006-12-05

申请号：US10389012

申请日：2003-03-14

Applicant: Barbara J. Brandhuber ,  Guy P. A. Vigers

Inventor： Barbara J. Brandhuber ,  Guy P. A. Vigers

IPC: C07K1/00

CPC classification number: A61K38/2006 ,  C07K14/7155 ,  C07K2299/00 ,  G01N33/6869 ,  G01N2333/715 ,  G06F19/16

Abstract: Crystals comprising a modified interleukin-1 type 1 receptor (IL-1R1) and one or more modulators of IL-1 activity are described. Methods of identifying potential inhibitors of IL-1 activity are also described. Compositions and methods for the treatment of IL-1 mediated diseases, such as rheumatoid arthritis, osteoarthritis, and other inflammatory conditions, are described.

Abstract translation: 描述了包含修饰的白细胞介素-1型受体（IL-1R1）和一种或多种IL-1活性调节剂的晶体。 还描述了识别IL-1活性的潜在抑制剂的方法。 描述了用于治疗IL-1介导的疾病如类风湿性关节炎，骨关节炎和其它炎性病症的组合物和方法。

公开(公告)号：US07078425B2

公开(公告)日：2006-07-18

申请号：US10512965

申请日：2003-04-30

Applicant: Robert D. Groneberg ,  David A. Mareska

Inventor： Robert D. Groneberg ,  David A. Mareska

IPC: A61K31/405 ,  A61K31/416 ,  C07D231/56 ,  C07D209/10

CPC classification number: C07D209/30 ,  C07D209/08 ,  C07D231/56

Abstract: Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein A, B, R1, R2, R3, and R4 are as defined in the specification. Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus

Abstract translation: 公开了式（I）的化合物及其药学上可接受的盐和前药，其中A，B，R 1，R 2，R 3， >和R 4如本说明书中所定义。 这些化合物是酪氨酸磷酸酶抑制剂，可用于治疗或预防II型糖尿病。 本发明还包括包含所述化合物的制剂，制备这些化合物的方法，治疗或预防II型糖尿病的方法

公开(公告)号：US20250066357A1

公开(公告)日：2025-02-27

申请号：US18946138

申请日：2024-11-13

Applicant: Array BioPharma Inc.

Inventor： James Francis BLAKE ,  Mark Laurence BOYS ,  Mark Joseph CHICARELLI ,  Adam Wade COOK ,  Mohamed S.A. ELSAYED ,  Jay Bradford FELL ,  John Peter FISCHER ,  Ronald Jay HINKLIN ,  Oren Teague MCNULTY ,  Macedonio J. MEJIA ,  Martha E. RODRIGUEZ ,  Christina Elizabeth WONG

IPC: C07D471/04 ,  C07D519/00

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed

公开(公告)号：US20240423960A1

公开(公告)日：2024-12-26

申请号：US18823257

申请日：2024-09-03

Applicant: ASTRAZENECA AB ,  Array BioPharma, Inc.

Inventor： Nicola Frances BATEMAN ,  Paul Richard GELLERT ,  Kathryn Jane HILL

IPC: A61K31/4184 ,  A61K9/00 ,  A61K9/14 ,  A61K9/48 ,  A61K47/22 ,  A61K47/36 ,  C07D235/06

Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament, and to processes for the preparation of said compositions.

公开(公告)号：US20240190843A1

公开(公告)日：2024-06-13

申请号：US18553214

申请日：2022-03-30

Applicant: Array BioPharma Inc.

Inventor： Katie Keaton BROWN ,  Aaron Keith GOODWIN

IPC: C07D401/14 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/506 ,  A61K31/53 ,  A61K39/00 ,  C07K16/28

CPC classification number: C07D401/14 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/506 ,  A61K31/53 ,  C07K16/2863 ,  A61K2039/505

Abstract: This Invention relates to a hemihydrate crystalline form of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine free base (Form 1). The invention also relates to pharmaceutical compositions comprising this crystalline form, and to methods of using the crystalline form and such compositions for the treatment of abnormal cell growth, such as cancer, in a mammal.

公开(公告)号：US20240124453A1

公开(公告)日：2024-04-18

申请号：US18512473

申请日：2023-11-17

Applicant: Array BioPharma Inc.

Inventor： James Francis BLAKE ,  Mark Laurence BOYS ,  Mark Joseph CHICARELLI ,  Adam Wade COOK ,  Mohamed S. A. ELSAYED ,  Jay Bradford FELL ,  John P. FISCHER ,  Ronald Jay HINKLIN ,  Yutong JIANG ,  Oren Teague MCNULTY ,  Macedonio J. MEJIA ,  Martha E. RODRIGUEZ ,  Christina Elizabeth WONG

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/14 ,  C07D471/10 ,  C07D513/10

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D401/14 ,  C07D471/10 ,  C07D513/10 ,  A61K45/06

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US11807651B2

公开(公告)日：2023-11-07

申请号：US17401892

申请日：2021-08-13

Applicant: Loxo Oncology, Inc. ,  Array BioPharma Inc.

Inventor： Charles Todd Eary ,  Stacey Spencer ,  Zack Crane ,  Katelyn Chando ,  Sylvie Asselin ,  Weidong Liu ,  Mike Welch ,  Adam Cook ,  Gabrielle R. Kolakowski ,  Andrew T. Metcalf ,  David A. Moreno ,  Tony P. Tang

IPC: C07D519/00 ,  C07D471/04

CPC classification number: C07D519/00 ,  C07D471/04

Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I




or a pharmaceutically acceptable salt thereof, as disclosed herein.

公开(公告)号：US20230241066A1

公开(公告)日：2023-08-03

申请号：US18092731

申请日：2023-01-03

Applicant: Array BioPharma Inc.

Inventor： Donald T. Corson ,  Christopher M. Lindemann ,  Daniel J. Watson

IPC: A61K31/517 ,  A61P35/00 ,  C07D471/04 ,  A61K31/437 ,  A61K45/06

CPC classification number: A61K31/517 ,  A61P35/00 ,  C07D471/04 ,  A61K31/437 ,  A61K45/06

Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.

公开(公告)号：US20230142839A1

公开(公告)日：2023-05-11

申请号：US17940902

申请日：2022-09-08

Applicant: Array BioPharma Inc.

Inventor： Joseph P. LYSSIKATOS ,  Julie Marie HICKS ,  Fredrik P. MARMSATER ,  Qian ZHAO

IPC: A61K31/337 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/513 ,  A61K31/517 ,  A61K39/395

CPC classification number: A61K31/337 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/513 ,  A61K31/517 ,  A61K39/3955

Abstract: This invention provides compounds of Formula I




wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.